ANI Pharmaceuticals | ANIP - Current Liabilities


ANI Pharmaceuticals reported $239.51M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Perrigo USD 997.6M 15.3M Mar/2026
Sun Pharmaceuticals INR 226.22B 7.93B Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026